Compare CVS Health Corp (CVS) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs The Coca-Cola Co K — how do they compare? CVS Health Corp trades at $86.3 (market cap $112.49B), while The Coca-Cola Co K trades at $87.39 (market cap $369.24B). The key difference: The Coca-Cola Co K is far larger — about 3.3× CVS Health Corp's market cap, and CVS Health Corp pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and The Coca-Cola Co K for 154 Days on average.
| CVS | KO | |
|---|---|---|
Market Cap | $112.49B | $369.24B |
Volume | 8,467,392 | 12,951,290 |
Sector | Health | Consumer Staples |
52-Week High | $110.60 | $91.99 |
52-Week Low | $70.08 | $66.37 |
Typical Hold Time | 83 Days | 154 Days |
Enterprise Value | $174.83B | $396.42B |
Dividend Yield | 3.02% | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Coca-Cola (KO) trades at $87.77, up 1.86% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 28.56% net income margin and 44.23% ROE, supported by consistent revenue growth. Analyst consensus is bullish with a $95.75 price target, though technical indicators highlight near-term resistance at $86-$87. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.
The outlook remains positive given KO's dividend track record and earnings momentum, but risks include regional demand volatility and high debt levels. Upside is supported by analyst targets, while technical weakness near key resistance may limit short-term gains. The stock offers value for income-focused investors despite macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
